Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus VITRAKVI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB D TARTRATE versus VITRAKVI.
NILOTINIB D-TARTRATE vs VITRAKVI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BCR-ABL tyrosine kinase inhibitor; binds to and inhibits the ATP-binding site of BCR-ABL, thereby inhibiting tyrosine kinase activity and downstream signaling pathways, leading to apoptosis in CML cells.
Larotrectinib is a selective inhibitor of the tropomyosin receptor kinases (TRK) A, B, and C. It binds to the ATP-binding site of TRK kinases, preventing their activation and downstream signaling pathways, thereby inhibiting proliferation and inducing apoptosis in tumors with NTRK gene fusions.
400 mg orally twice daily, approximately 12 hours apart, with food.
100 mg orally twice daily
None Documented
None Documented
17 hours (terminal elimination half-life); supports once-daily dosing
Terminal elimination half-life is approximately 16.2 hours (range 12-20 h) in patients; supports twice-daily dosing.
Fecal (93%), renal (4%)
Primarily hepatic metabolism, with 39% recovered in feces (36% as unchanged drug) and 18% in urine (0.5% unchanged).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor